Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
José Mª
José M. Álvarez Pastor, Salamanca ES
| Patent application number | Description | Published |
|---|---|---|
| 20110253901 | DEVICE FOR DETECTING HIGHLY ENERGETIC PHOTONS | 10-20-2011 |
José M. Barral, Galveston, TX US
| Patent application number | Description | Published |
|---|---|---|
| 20090325874 | Inhibition of inositol 1,4,5-triphosphate receptor calcium channel/cytochrome c interactions and uses thereof - The present invention demonstrates selective pharmacological targeting and inhibition of apoptotic calcium release in lymphocytes from inositol 1,4,5-trisphosphate receptor calcium channels may enhance the immunologic response to tumor cells which have acquired adaptive changes in death receptor signaling to promote survival. The present invention provides methods of protecting lymphocytes from tumor cell-induced apoptotic cell death by contacting lymphocytes with one or more cell permeant peptide(s). Also provided are methods of inhibiting caspase activation and blocking calcium release by blocking binding of cytochrome c to the inositol 1,4,5-triphosphate receptor calcium channel. In addition, methods are provided to treat a cancer, enhance immunologic response by administering or applying small molecule inhibitor, e.g., cell permeant peptides specific for the cytochrome c binding domain of inositol 1,4,5-triphosphate receptor calcium channel. | 12-31-2009 |
José M. Barral, Galveston, TX US
| Patent application number | Description | Published |
|---|---|---|
| 20090325874 | Inhibition of inositol 1,4,5-triphosphate receptor calcium channel/cytochrome c interactions and uses thereof - The present invention demonstrates selective pharmacological targeting and inhibition of apoptotic calcium release in lymphocytes from inositol 1,4,5-trisphosphate receptor calcium channels may enhance the immunologic response to tumor cells which have acquired adaptive changes in death receptor signaling to promote survival. The present invention provides methods of protecting lymphocytes from tumor cell-induced apoptotic cell death by contacting lymphocytes with one or more cell permeant peptide(s). Also provided are methods of inhibiting caspase activation and blocking calcium release by blocking binding of cytochrome c to the inositol 1,4,5-triphosphate receptor calcium channel. In addition, methods are provided to treat a cancer, enhance immunologic response by administering or applying small molecule inhibitor, e.g., cell permeant peptides specific for the cytochrome c binding domain of inositol 1,4,5-triphosphate receptor calcium channel. | 12-31-2009 |
José M. Carballido Herrera, Basel CH
| Patent application number | Description | Published |
|---|---|---|
| 20100183602 | Induction of Tolerogenic Phenotype in Mature Dendritic Cells - The present invention relates to the use of a CD45 binding molecule to modulate the function of Dendritic cells. In particular the present invention relates to the use of a CD45 binding molecule to induce tolerogenic dendritic cells, useful in the treatment of diseases or disorders such as autoimmune diseases, transplant rejection. | 07-22-2010 |
| 20110076270 | Therapeutic Binding Molecules - A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical. | 03-31-2011 |
José M. Carballido Herrera, Basel CH
| Patent application number | Description | Published |
|---|---|---|
| 20110076270 | Therapeutic Binding Molecules - A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical. | 03-31-2011 |
José M. Carballido Herrera, Vienna AT
| Patent application number | Description | Published |
|---|---|---|
| 20090208997 | GPR18 as a Biomaker for TH1 Mediated Immune Response - The present invention provides the use of GPR18 in diseases or disorders mediated by Th1 cell activation. | 08-20-2009 |
| 20090317827 | Receptor In Dendritic Cells - The present invention provides the use of GPR91 as a target in dendritic cells. | 12-24-2009 |
José M. Carballido Herrera, Allschwil CH
| Patent application number | Description | Published |
|---|---|---|
| 20120034231 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES - The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12Rβ2 chain) as well as IL23 receptor (together with IL23Rα chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNγ production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders. | 02-09-2012 |
José M. Catala-Civera, Valencia ES
| Patent application number | Description | Published |
|---|---|---|
| 20080292813 | Microwave Heating Device With Irradiation Arrangement - The invention relates to a heating device ( | 11-27-2008 |
José M. Catala-Civera, Valencia ES
| Patent application number | Description | Published |
|---|---|---|
| 20080292813 | Microwave Heating Device With Irradiation Arrangement - The invention relates to a heating device ( | 11-27-2008 |
José M. Gomora Elena, Madrid ES
| Patent application number | Description | Published |
|---|---|---|
| 20100216173 | CITRULLINATED FIBRIN-FILAGGRIN CHIMERIC POLYPEPTIDE CAPABLE OF DETECTING THE ANTIBODIES GENERATED IN RHEUMATOID ARTHRITIS - The present invention concerns a chimeric polypeptide, capable of detecting the antibodies generated in rheumatoid arthritis, comprising at least two citrulinated peptide subunits: (i) one derived from the α or β chain of the fibrin and (ii) a second derived from the filaggrin. In addition, the invention comprises an antigenic composition, a method and a kit for the diagnosis of rheumatoid arthritis, from the detection of the autoantibodies generated during the course of said disease. | 08-26-2010 |
José M. Gomora Elena, Madrid ES
| Patent application number | Description | Published |
|---|---|---|
| 20100216173 | CITRULLINATED FIBRIN-FILAGGRIN CHIMERIC POLYPEPTIDE CAPABLE OF DETECTING THE ANTIBODIES GENERATED IN RHEUMATOID ARTHRITIS - The present invention concerns a chimeric polypeptide, capable of detecting the antibodies generated in rheumatoid arthritis, comprising at least two citrulinated peptide subunits: (i) one derived from the α or β chain of the fibrin and (ii) a second derived from the filaggrin. In addition, the invention comprises an antigenic composition, a method and a kit for the diagnosis of rheumatoid arthritis, from the detection of the autoantibodies generated during the course of said disease. | 08-26-2010 |
José M. Guillén-Rodríguez, Tucson, AZ US
| Patent application number | Description | Published |
|---|---|---|
| 20110066147 | SYSTEM AND METHOD FOR PREDICTING LESION SIZE SHORTLY AFTER ONSET OF RF ENERGY DELIVERY - Lesion size or volume prediction shortly after the onset of an ablation procedure can inform or control the ablation procedure. The prediction and/or control is made without regard to an actual detected temperature in the vicinity of the ablation electrodes. As a consequence, the system has utility with irrigated catheter constructions and other situations in which local irrigation in the vicinity of an ablation site would otherwise interfere with a prediction or control scheme that solely relies upon temperature measurements. | 03-17-2011 |
José M. Guillén-Rodríguez, Tucson, AZ US
| Patent application number | Description | Published |
|---|---|---|
| 20110066147 | SYSTEM AND METHOD FOR PREDICTING LESION SIZE SHORTLY AFTER ONSET OF RF ENERGY DELIVERY - Lesion size or volume prediction shortly after the onset of an ablation procedure can inform or control the ablation procedure. The prediction and/or control is made without regard to an actual detected temperature in the vicinity of the ablation electrodes. As a consequence, the system has utility with irrigated catheter constructions and other situations in which local irrigation in the vicinity of an ablation site would otherwise interfere with a prediction or control scheme that solely relies upon temperature measurements. | 03-17-2011 |
José Mª Jimeno Donaque, Madrid ES
| Patent application number | Description | Published |
|---|---|---|
| 20100267732 | Prognostic Molecular Markers for ET-743 Treatment - The present invention relates to the use of ecteinascidin 743 in human patients having certain molecular markers profile which has been associated with the outcome of ET-743 chemotherapy. In particular, the invention relates to the use of ecteinascidin 743 in patients having high expression levels of XPG mRNA or protein and/or having a “wild type” genotype for Asp1104His SNP of XPG gene. | 10-21-2010 |
José Mª Jimeno Doñaque, Madrid ES
| Patent application number | Description | Published |
|---|---|---|
| 20100267732 | Prognostic Molecular Markers for ET-743 Treatment - The present invention relates to the use of ecteinascidin 743 in human patients having certain molecular markers profile which has been associated with the outcome of ET-743 chemotherapy. In particular, the invention relates to the use of ecteinascidin 743 in patients having high expression levels of XPG mRNA or protein and/or having a “wild type” genotype for Asp1104His SNP of XPG gene. | 10-21-2010 |
| 20110015135 | Antitumoral Treatments - The present invention relates to combinations of PM02734 with another anticancer drug selected from Cisplatin, Gemcitabine, Paclitaxel, Oxaliplatin, 5-Fluorouracil, Trabectedin, Rapamycin, and Sunitinib, and the use of these combinations in the treatment of cancer. | 01-20-2011 |
José Mª Jimeno Doñaque, Madrid ES
| Patent application number | Description | Published |
|---|---|---|
| 20110015135 | Antitumoral Treatments - The present invention relates to combinations of PM02734 with another anticancer drug selected from Cisplatin, Gemcitabine, Paclitaxel, Oxaliplatin, 5-Fluorouracil, Trabectedin, Rapamycin, and Sunitinib, and the use of these combinations in the treatment of cancer. | 01-20-2011 |